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Background: Evidence suggests that neurotropic infectious agents might be involved in bipolar disorder. So far,
few have been written for the association between parasitic infection and bipolar disorder. Filariasis is a parasitic
disease acting ruthlessly via mosquitos and affecting more than 120 million people worldwide. We present here, to
our knowledge, the first description of a filariasis infected manic bipolar disorder patient fully improved in terms of
psychiatric symptoms by anti-heminthic treatment.
Case presentation: The patient is a 31 years-old man native of Congo. At inclusion, he presented a severe manic
episode with dangerous behaviour unresolved by classic treatments. A diagnosis of filariasis bancrofti infection was
made after the discovery of a systemic hypereosinophilia. Therefore, a bi-therapy of anthelmintics was conducted
allowing a successful improvement with clear reduction of agitation and aggressive behaviours that could not be
attributed to a modification of psychotropic treatments or filarial encephalopathy or acute disseminated
encephalomyelitis.
Conclusion: The ineffectiveness of psychotropic treatment of a manic episode requires the evaluation of co-morbid
medical conditions such as infections which can interfere with adequate mood stabilizing medication. Filariasis by
inducing chronic inflammation and immunopathologic reactions seems to play a major role in infected affective
disorders patients by changing levels of cytokines of the Th1 system or indirectly damaging the brain tissue. The
beneficial combination of antihelmintics and mood stabilizers, in this case, could be explained by the potential of
such association to downregulate neuroinflammation and excitotoxicity processes.
Altogether, these data pinpoint the requirement to explore the parasitic infectious status in case of bipolar disorder
patients resistant to classic treatments and originating or living in endemic geographical areas.
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Evidence suggests that neurotropic infectious agents might
be involved in bipolar disorder. Therefore, specific treat-
ments have been proposed as Amantadine, an antiviral
compound against BDV (Borna Disease Virus), which
seem to exert an antiviral and an antidepressive action in
depressive infected bipolar type I patients [1]. Isoniazid
which has been developed for prevention and treat-
ment of tuberculosis, exhibits antidepressant properties.* Correspondence: nora.hamdani@ach.aphp.fr
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reproduction in any medium, provided the orMinocycline, a tetracycline seems to reduce depressive
symptoms among bipolar disorder patient [2] while
clarithromycin, ciprofloxacin, erythromycin and amoxicil-
lin [3,4] can lead to a manic episode and therefore are
called “antibiomania” [5]. It has been suggested that mood
stabilizing properties of macrolides could act via their
interference in the mitochondrial functioning of neurons
[6]. Filariasis is a parasitic disease acting ruthlessly via
mosquitos in regions of Asia, Africa, Central, South
America and Pacific Island nations, with more than 120
million people infected. 90% of this infection is caused by
W. bancrofti with about 80 countries known to be en-
demic areas [7].The most important filarial disease for
humans is lymphatic filariasis in which the adult wormsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quently affected (sex ratio 10:1) in their third or 4th decade
[7]. The incubation period from mosquito bite may be
comprised between 4 weeks and more than six months [7].
Usually asymptomatic, rare cases of neurological symptoms
have been described. In monkeys, filarial worms were ob-
served in the bulb, the protuberance, and the cervical cord
[8]. In humans, several authors described cases with paraly-
sis [9], hemiplegia [10,11], troubles of consciousness [12].
In addition, filariasis is suspected to cause insomnia, mental
depression, irritability and severe headaches [13]. A rela-
tionship between central nervous symptoms and filariasis
appears to be established in these cases, since the surgical
removal of adult L.boa, and treatment of the W. bancrofti
infections with specific treatment, was followed by the
disappearance of symptoms. For to the authors, the neu-
ropsychiatric symptoms observed may be due to the pres-
ence of adult worms in vital organs, but the possibility of
systemic reactions caused by allergic sensitization of the
host to filarial protein has to be considered, regardless of
the location of the worms [13]. A post mortem study of fil-
arial encephalitis showed a diffuse inflammation of the
white matter (in a less extent, the grey matter), perivascular
inflammation and a dramatic allergic reaction explaining
serious neurologic symptoms [14].
Chemotherapy (antihelmintics) is now considered as
the most cost-effective tool to potentially interrupt
transmission even among asymptomatic patients.
We report successful improvement of manic symp-
toms when adding anthelmintics among an infected bi-
polar disorder patient refractory to usual treatments.
Case presentation
The patient is a 31 years-old man with bipolar disorder
(Diagnostic and Statistical Manual of Mental Disorders,
DSM-IV criteria). The patient had a previous psychiatric
history of depression and delusions 3 years before but the
diagnosis of bipolar disorder was not evoked. It was the
third relapse for the patient and two previous hospitaliza-
tions have been conducted in Congo. The patient was
treated by haloperdidol before. There was no history of
substance abuse. Native of Congo, he was admitted in a
psychiatric ward for a manic episode with agitation, irrit-
ability, logorrhea, aggressive behaviour and delusions (per-
secutive, mystic and megalomaniac) (Young Mania Rating
Scale, YMRS=43). The excitation and insomnia escalate to
become dangerous, including physical violence needing
physical restraint and seclusion. Pharmacological agents
used to treat agitation including benzodiazepines, first-
and second-generation antipsychotic drugs, and mood sta-
bilizers showed no efficacy in spite of good compliance.
The patient received clonazepam (8 mg) for several weeks
with loxapine (400 mg) then cyamemazine (400 mg/day)
and aripiprazole (25 mg) then olanzapine. Amisulpridewas conducted at 1200 mg/ day for several weeks. Finally,
valproic acid was administrated at 1250 mg/per day for sev-
eral weeks. Neurological and somatic examination of the
patient was normal. The MRI of brain was normal. Bio-
logical testing including routine blood counting and urine
examination were normal with exception of a systemic
hypereosinophilia which furhter lead to the diagnosis of a
filariasis bancrofti infection using an immunodiagnosic
method. However, we did not find any filariasis symptoms
in our patient. A bi-therapy of anthelmintics including an
association of ivermectin and albendazole was conducted.
Two weeks after the initiation of anti-filariasis treatment, a
successful improvement was observed with clear reduction
of agitation and aggressive behaviours (YMRS=9) that
could not be attributed to a modification of psychotropic
treatments (modification of dosages), filarial encephalop-
athy or acute disseminated encephalomyelitis (absence of
confusion, poor memory, incoordination, speech pro-
blems, lethargy, irritability, confusion ataxia, seizures and
demyelinisation of the white matter). Euthymia was
obtained simultaneously with the elimination of the para-
site (according to immunodiagnosis status).
Discussion
The ineffectiveness of psychotropic treatment of a manic
episode requires the evaluation of co-morbid medical
conditions such as infections, which can interfere with
adequate mood stabilizing medication. The key pharma-
cological regimens in the management of lymphatic
filariasis are diethylcarbamazine, albendazole, and iver-
mectin either used alone or in combination. However,
combination therapy seems to have a better macrofilarial
effect than monotherapy [15]. How could we explain the
adjunctive effect of antihelmintics to mood stabilizers
efficacy? To date, antiparasitic treatment has not been
described to be effective among infected bipolar disorder
patients. Ivermectin show unexpectedly poor penetration
of the blood brain barrier [16]. One explanation could
be given by the fact that ivermectin, which is a semi-
synthetic macrolide, may have mood stabilizing properties
via their interference in the mitochondrial functioning
of neurons [6]. A contrario, albendazole seems to cross
the blood-brain barrier and is prescribed to prevent fil-
arial encephalopathy [17] or encephalomyelitis. It has
been demonstrated that repeated albendazole treatment
cause significant increases in production of the Th2
cytokines IL-5 and IL-13, by peripheral blood leuko-
cytes [18]. According to the well known Th1 pathway
overstimulation among manic patients with consequent
proinflamatory cytokines production for review, [19],
2the Th2-mediated effect of albendazole can potentially
lead to the inhibition of such Th1 pathway allowing
anti-inflammatory responses and systemic inflammation
downregulation. Hence, filariasis which induce chronic
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pro-inflammatory Th1 cytokines (IFN-gamma, TNF-alpha,
GM-CSF, IL-1alpha, and IL-8) [20] or immunopathological-
related brain tissue damage could be alleviated by
downregulation neuroinflammation and excitotoxicity
properties of mood stabilizers in conjunction with
antihelmintics.
Conclusion
The treatment of bipolar disorder patients carrying a
parasitic infection, by specific anti-infectious drugs could
be useful thanks to their immuno-modulatory properties
[21] and have to be evoked especially among patients
native from or living in endemic countries.
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